skip to content
Characterizing the drug development pipeline for precision medicines Preview this item
ClosePreview this item
Checking...

Characterizing the drug development pipeline for precision medicines

Author: Amitabh Chandra; Craig L Garthwaite; Ariel Dora Stern; National Bureau of Economic Research,
Publisher: Cambridge, Mass. : National Bureau of Economic Research, 2017.
Series: Working paper series (National Bureau of Economic Research), no. 24026.
Edition/Format:   eBook : Document : EnglishView all editions and formats
Summary:
Precision medicines -- therapies that rely on genetic, epigenetic, and protein biomarkers -- create a better match between individuals with specific disease subtypes and medications that are more effective for those patients. These treatments are expected to be both more effective and more expensive than conventional therapies, implying that their introduction is likely to have a meaningful effect on health care  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Amitabh Chandra; Craig L Garthwaite; Ariel Dora Stern; National Bureau of Economic Research,
OCLC Number: 1012492089
Notes: "November 2017"
Description: 1 online resource (52, xvi pages) : illustrations.
Series Title: Working paper series (National Bureau of Economic Research), no. 24026.
Responsibility: Amitabh Chandra, Craig Garthwaite, Ariel Dora Stern.

Abstract:

Precision medicines -- therapies that rely on genetic, epigenetic, and protein biomarkers -- create a better match between individuals with specific disease subtypes and medications that are more effective for those patients. These treatments are expected to be both more effective and more expensive than conventional therapies, implying that their introduction is likely to have a meaningful effect on health care spending patterns. In addition, precision medicines can change the expected profitability of therapies both by allowing more sophisticated pricing systems and potentially decreasing the costs of drug development through shorter and more focused trials. As a result, this could change the types of products that can be profitably brought to market. To better understand the landscape of precision medicines, we use a comprehensive database of over 130,000 global clinical trials, over the past two decades. We identify clinical trials for likely precision medicines (LPMs) as those that use one or more relevant biomarkers. We then further segment trials based on the nature of the biomarker(s) used and other trial features with economic implications. Given potential changes in the incentives for bringing products to market, we also examine the relative importance of public agencies such as the National Institutes of Health (NIH) and different types of private firms in developing precision medicines.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1012492089> # Characterizing the drug development pipeline for precision medicines
    a schema:MediaObject, schema:Book, schema:CreativeWork ;
    library:oclcnum "1012492089" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/mau> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/4629103177#Topic/personalized_medicine_economic_aspects> ; # Personalized medicine--Economic aspects
    schema:about <http://experiment.worldcat.org/entity/work/data/4629103177#Topic/drug_development_economic_aspects> ; # Drug development--Economic aspects
    schema:about <http://experiment.worldcat.org/entity/work/data/4629103177#Topic/biopharmaceutics_economic_aspects> ; # Biopharmaceutics--Economic aspects
    schema:about <http://experiment.worldcat.org/entity/work/data/4629103177#Topic/pharmacogenetics_economic_aspects> ; # Pharmacogenetics--Economic aspects
    schema:author <http://experiment.worldcat.org/entity/work/data/4629103177#Person/garthwaite_craig_l> ; # Craig L. Garthwaite
    schema:author <http://experiment.worldcat.org/entity/work/data/4629103177#Person/chandra_amitabh> ; # Amitabh Chandra
    schema:author <http://experiment.worldcat.org/entity/work/data/4629103177#Person/stern_ariel_dora> ; # Ariel Dora Stern
    schema:bookFormat schema:EBook ;
    schema:datePublished "2017" ;
    schema:description "Precision medicines -- therapies that rely on genetic, epigenetic, and protein biomarkers -- create a better match between individuals with specific disease subtypes and medications that are more effective for those patients. These treatments are expected to be both more effective and more expensive than conventional therapies, implying that their introduction is likely to have a meaningful effect on health care spending patterns. In addition, precision medicines can change the expected profitability of therapies both by allowing more sophisticated pricing systems and potentially decreasing the costs of drug development through shorter and more focused trials. As a result, this could change the types of products that can be profitably brought to market. To better understand the landscape of precision medicines, we use a comprehensive database of over 130,000 global clinical trials, over the past two decades. We identify clinical trials for likely precision medicines (LPMs) as those that use one or more relevant biomarkers. We then further segment trials based on the nature of the biomarker(s) used and other trial features with economic implications. Given potential changes in the incentives for bringing products to market, we also examine the relative importance of public agencies such as the National Institutes of Health (NIH) and different types of private firms in developing precision medicines."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/4629103177> ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/4629103177#Series/nber_working_paper_series> ; # NBER working paper series ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/4629103177#Series/working_paper_series_national_bureau_of_economic_research> ; # Working paper series (National Bureau of Economic Research) ;
    schema:name "Characterizing the drug development pipeline for precision medicines"@en ;
    schema:productID "1012492089" ;
    schema:publisher <http://experiment.worldcat.org/entity/work/data/4629103177#Organization/national_bureau_of_economic_research> ; # National Bureau of Economic Research,
    schema:url <http://www.nber.org/papers/w24026> ;
    schema:url <http://dx.doi.org/10.3386/w24026> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1012492089> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/4629103177#Organization/national_bureau_of_economic_research> # National Bureau of Economic Research,
    a schema:Organization ;
    schema:name "National Bureau of Economic Research," ;
    .

<http://experiment.worldcat.org/entity/work/data/4629103177#Person/chandra_amitabh> # Amitabh Chandra
    a schema:Person ;
    schema:familyName "Chandra" ;
    schema:givenName "Amitabh" ;
    schema:name "Amitabh Chandra" ;
    .

<http://experiment.worldcat.org/entity/work/data/4629103177#Person/garthwaite_craig_l> # Craig L. Garthwaite
    a schema:Person ;
    schema:familyName "Garthwaite" ;
    schema:givenName "Craig L." ;
    schema:name "Craig L. Garthwaite" ;
    .

<http://experiment.worldcat.org/entity/work/data/4629103177#Person/stern_ariel_dora> # Ariel Dora Stern
    a schema:Person ;
    schema:familyName "Stern" ;
    schema:givenName "Ariel Dora" ;
    schema:name "Ariel Dora Stern" ;
    .

<http://experiment.worldcat.org/entity/work/data/4629103177#Series/nber_working_paper_series> # NBER working paper series ;
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1012492089> ; # Characterizing the drug development pipeline for precision medicines
    schema:name "NBER working paper series ;" ;
    .

<http://experiment.worldcat.org/entity/work/data/4629103177#Series/working_paper_series_national_bureau_of_economic_research> # Working paper series (National Bureau of Economic Research) ;
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1012492089> ; # Characterizing the drug development pipeline for precision medicines
    schema:name "Working paper series (National Bureau of Economic Research) ;" ;
    .

<http://experiment.worldcat.org/entity/work/data/4629103177#Topic/biopharmaceutics_economic_aspects> # Biopharmaceutics--Economic aspects
    a schema:Intangible ;
    schema:name "Biopharmaceutics--Economic aspects"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/4629103177#Topic/drug_development_economic_aspects> # Drug development--Economic aspects
    a schema:Intangible ;
    schema:name "Drug development--Economic aspects"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/4629103177#Topic/personalized_medicine_economic_aspects> # Personalized medicine--Economic aspects
    a schema:Intangible ;
    schema:name "Personalized medicine--Economic aspects"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/4629103177#Topic/pharmacogenetics_economic_aspects> # Pharmacogenetics--Economic aspects
    a schema:Intangible ;
    schema:name "Pharmacogenetics--Economic aspects"@en ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.